Pulmonx cuts FY25 revenue view to $89M-$90M from $90M-$92M

Consensus $90.69M. The company said, “Pulmonx (LUNG) is updating its 2025 financial outlook and expects full year 2025 total revenue to be in the range of $89 million to $90 million. The Company expects gross margin for the full year 2025 to be approximately 73%. Pulmonx expects total operating expenses for the full year 2025 to fall within the range of $125 million to $126 million, inclusive of approximately $21 million of non-cash stock-based compensation. The Company’s updated guidance does not anticipate any potential impact from future tariffs or trade policy changes, or their effects on the global macroeconomic environment, including foreign currency fluctuations.”